CIK 0001438533 · Large accelerated filer
Travere Therapeutics, Inc.
Sign in to watch- Ticker
- TVTX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- CA
- Entity type
- operating
- EIN
- 262383102
- Phone
- 888-969-7879
- Business address
- 3611 VALLEY CENTRE DR, SUITE 300, SAN DIEGO, CA, 92130
- Former names
- Retrophin, Inc., Desert Gateway, Inc.
- SCHEDULE 13G/A Stake Statement of Beneficial Ownership
- 4 Open-market sale CHIEF FINANCIAL OFFICER sold 48 shares at $13.14 ($631)
- 144 Insider Sale of Securities
- ARS Other Annual Report to Security Holders
- DEFA14A Proxy Proxy Materials
- DEF 14A Proxy Proxy Statement
- 8-K Event Other events
- 10-K Report Annual Report
- 8-K Event Results of operations
- SCHEDULE 13G/A Stake Statement of Beneficial Ownership
- SCHEDULE 13G/A Stake Statement of Beneficial Ownership
- SCHEDULE 13G/A Stake Statement of Beneficial Ownership
- 4 Planned sale SENIOR VICE PRESIDENT, R&D sold 5,200 shares at $23.53 ($122,356)
- 4 Planned sale SVP, GC & CORPORATE SECRETARY sold 8,000 shares at $23.53 ($188,240)
- 4 Planned sale SVP, CHIEF ACCOUNTING OFFICER sold 54,244 shares at $25.00 ($1,356,100)
- 4 Planned sale CHIEF COMMERCIAL OFFICER sold 5,642 shares at an average $24.33 ($137,276)
- 4 Planned sale CHIEF EXECUTIVE OFFICER sold 11,375 shares at $24.04 ($273,455)
- 4 Open-market sale CHIEF MEDICAL OFFICER sold 2,568 shares at $23.53 ($60,426)
- 144 Insider Sale of Securities
- 144 Insider Sale of Securities
Page 13 of 65 · 1,286 filings